IRTCiRhythm Holdings, Inc.

Ticker: IRTC | Price: $93.47 | Today's Change: +5.40%

---

What Happened

iRhythm Holdings, Inc. filed an 8-K with the SEC on November 12, 2026, reporting financial results for the third quarter of fiscal year 2026 under Items 7.01, 8.01, and 9.01. Revenue from contracts with customers reached $538.2 million for Q3 FY2026, reflecting continued top-line scale in the company's cardiac monitoring business. At the same time, the company posted a net loss of $30.7 million and an operating loss of $59.7 million for the quarter, with both basic and diluted earnings per share coming in at -$1.57.

---

Why It Matters

For investors, the Q3 FY2026 results present a mixed picture: iRhythm continues to generate substantial revenue, but profitability remains elusive. The gap between the operating loss (-$59.7M) and the net loss (-$30.7M) suggests meaningful non-operating income — such as interest income or other items — is partially offsetting operational cash burn, though the company has not yet closed the path to breakeven on an operating basis. The stock's 5.40% move higher on the day of this report suggests that the market may be interpreting these results favorably relative to expectations — though the precise consensus figures against which to benchmark are not available within this filing. Investors following our existing coverage will recall that StockWatch initiated coverage of IRTC on September 23, 2026; today's results provide a material data point to track against the operational trajectory outlined at that time.

---

Analysis

iRhythm's $538.2 million in quarterly revenue is a notable figure for a med-tech company in the ambulatory cardiac monitoring space, and signals that the company's Zio patch platform continues to drive strong commercial uptake. However, the persistence of an operating loss exceeding $59 million raises ongoing questions about the timeline to profitability and the company's ability to convert top-line scale into sustainable operating leverage.

Key items to watch going forward:

• Operating leverage: Whether revenue growth is translating into a narrowing operating loss margin over successive quarters — the absolute operating loss of $59.7M on $538.2M in revenue implies an operating margin of approximately -11%, a figure investors will want to see improve.
• Non-operating offsets: The roughly $29 million gap between operating loss and net loss warrants scrutiny — understanding what is driving that offset (interest income, one-time items, etc.) matters for the quality of reported earnings.
• Guidance and forward commentary: Any updated full-year outlook provided alongside this filing will be crucial context for assessing whether Q3's revenue run-rate is sustainable or accelerating.
• Path to profitability: With a loss per share of -$1.57 still on the books, the timeline and mechanism for reaching breakeven remain the central question for long-term holders.

The day's positive price reaction suggests the market is reading these results as at least in line with or ahead of expectations, even if the absolute loss figures are substantial. As always, the direction of travel — not just the destination — is what matters most for a growth-stage medical device company like iRhythm.

---

Disclaimer

This report is a news and informational analysis based solely on data contained in iRhythm Holdings, Inc.'s SEC filing dated November 12, 2026, and publicly available market data. It does not constitute investment advice, an offer or solicitation to buy or sell any security, or a recommendation of any kind. Readers should conduct their own due diligence and consult a qualified financial professional before making any investment decision. StockWatch and its contributors may hold positions in securities mentioned.

Existing Coverage

StockWatch has full coverage on IRTC, published 2026-09-23. Read our Initiating Coverage →

Source

Filed with the SEC on 2026-11-12. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/1388658/000110465926125580/tm2629543d1_8k.htm